Literature DB >> 18434494

Prevalence, impact, and prognosis of multisomatoform disorder in primary care: a 5-year follow-up study.

Jeffrey L Jackson1, Kurt Kroenke.   

Abstract

BACKGROUND: To determine the prevalence, impact, and prognosis of multisomatoform disorder (MSD) over a 5-year period in a primary care population. Although somatization is prevalent in primary care, patients rarely meet Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for somatization disorder. MSD, defined as > or = 3 bothersome, medically unexplained somatic symptoms, has been proposed as a more inclusive disorder.
METHODS: A total of 500 adults presenting to a primary care clinic with a physical symptom were screened with the Primary Care Evaluation of Mental Disorders. Symptom count was assessed with the Patient Health Questionnaire 15-item somatic symptom scale. Additional baseline measures included functional status and symptom characteristics. Follow-up surveys at 2 weeks, 3 months, and 5 years assessed functioning, symptom outcome, psychiatric diagnoses, and patient satisfaction. Physician surveys assessed encounter difficulty. Utilization was obtained from our health database.
RESULTS: MSD had an 8% prevalence at both baseline (n = 38/500) and at 5 years (n = 33/387). MSD persisted in 21% of those with MSD at baseline, and developed in 7% of those without MSD at baseline. MSD at baseline was a predictor of MSD at 5 years (relative risk (RR) = 2.7, 1.5-5.1). MSD patients were more likely to have comorbid mental disorders (RR = 1.5, 1.1-2.3) and be rated "difficult" by their clinicians (p = .02). They also reported worse functional status at all time points assessed (p < .001 for all), were less likely to experience symptom improvement, and had higher utilization rates (34.1 versus 23.1 visits; p = .006).
CONCLUSIONS: MSD identifies a group of patients who are less likely to experience symptom improvement and have significant functional impairment and higher utilization rates.

Entities:  

Mesh:

Year:  2008        PMID: 18434494     DOI: 10.1097/PSY.0b013e31816aa0ee

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  34 in total

1.  Sustained pain reduction through affective self-awareness in fibromyalgia: a randomized controlled trial.

Authors:  Michael C Hsu; Howard Schubiner; Mark A Lumley; John S Stracks; Daniel J Clauw; David A Williams
Journal:  J Gen Intern Med       Date:  2010-06-08       Impact factor: 5.128

2.  The cost of somatisation among the working-age population in England for the year 2008-2009.

Authors:  Sarah L Bermingham; Alan Cohen; John Hague; Michael Parsonage
Journal:  Ment Health Fam Med       Date:  2010-06

3.  Medically unexplainable somatic symptoms: a coat with many psychiatric colors.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Medically unexplained physical symptoms.

Authors:  Jeffrey L Jackson; Susan George; Sherri Hinchey
Journal:  J Gen Intern Med       Date:  2009-04       Impact factor: 5.128

Review 5.  Somatoform disorders and medically unexplained symptoms in primary care.

Authors:  Heidemarie Haller; Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

6.  Functional Somatic Symptoms.

Authors:  Casper Roenneberg; Heribert Sattel; Rainer Schaefert; Peter Henningsen; Constanze Hausteiner-Wiehle
Journal:  Dtsch Arztebl Int       Date:  2019-08-09       Impact factor: 5.594

Review 7.  Health care utilization and poor reassurance: potential predictors of somatoform disorders.

Authors:  Paul R Puri; Joel E Dimsdale
Journal:  Psychiatr Clin North Am       Date:  2011-09

8.  Diagnostic accuracy of predicting somatization from patients' ICD-9 diagnoses.

Authors:  Robert C Smith; Joseph C Gardiner; Zhehui Luo; Kathryn Rost
Journal:  Psychosom Med       Date:  2009-03-17       Impact factor: 4.312

9.  A randomized trial of treatments for high-utilizing somatizing patients.

Authors:  Arthur J Barsky; David K Ahern; Mark R Bauer; Nyryan Nolido; E John Orav
Journal:  J Gen Intern Med       Date:  2013-03-14       Impact factor: 5.128

10.  Assessing medically unexplained symptoms: evaluation of a shortened version of the SOMS for use in primary care.

Authors:  Cristina Fabião; M C Silva; António Barbosa; Manuela Fleming; Winfried Rief
Journal:  BMC Psychiatry       Date:  2010-05-17       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.